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Background: Social observation is one of the main ways to gain experience. Similar to first-
person experience, observational experience affects the effectiveness of subsequent treatments. 
Yet, it is still undetermined whether the influence of social observation on placebo and nocebo 
effects to subsequent treatments remains even if related experience occurred a few days ago.
Methods: Eighty-two participants were recruited and each of them was randomly assigned to 
one of the four experimental groups acquiring first-person or observational experience, which 
was either effective or ineffective. For the first-person groups, participants were presented with 
pain cues paired with pain stimuli in person. In the effective condition, low pain cues were paired 
with low pain stimuli, and high pain cues were paired with high pain stimuli. In contrast, the 
associations between cues and pain stimuli were not established in the ineffective condition. Simi-
larly, for the observational groups, participants received effective/ineffective treatment through 
observation. Five or six days later, all participants underwent a conditioning phase followed by 
a test phase composed of two tests, where participants were asked to report their perceived pain.
Results: Placebo and nocebo responses to subsequent treatments can be affected by prior 
experience gained several days ago regardless of acquisition ways, and both placebo and nocebo 
responses in the effective condition were significantly larger than those in the ineffective condi-
tion. Furthermore, once placebo and nocebo effects were elicited, the latter was more persistent, 
while the former was more likely to diminish.
Conclusion: First-person and observational experience obtained a few days ago could affect 
the following treatments, which advance our understanding of the crucial and sustained influ-
ence of social observation on placebo analgesia and nocebo hyperalgesia, and provide insights 
into clinical applications.
Keywords: social observation, prior experience, placebo analgesia, nocebo hyperalgesia, 
conditioning, expectancy
Introduction
Learning plays an important role in the induction of placebo/nocebo responses via first-
person experience and social observation,1,2 two main acquisition ways that shape prior 
experience thereby altering our perceived effectiveness of treatments.3 Numerous clinical 
observations have demonstrated the pivotal role of prior first-person experience in placebo 
analgesia and nocebo hyperalgesia,4–11 that is, robust placebo/nocebo responses can be 
induced after repeated exposure to positive/negative treatments in person.4–11 Similar 
situations can be observed in laboratory settings, where prior first-person experience of 
positive treatments induces strong placebo responses; negative treatments, on the other 
hand, may reduce placebo responses and even lead to nocebo responses.8,12,13
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Similar to first-person experience, social observation 
can also generate strong placebo analgesia and nocebo 
hyperalgesia.14–18 However, it is still unclear whether the 
placebo/nocebo responses generated by social observation 
are comparable to those generated by first-person experience, 
in terms of their sustainability. If the effect of social observa-
tion can sustain, it would be of great significance in clinical 
applications, as patients could obtain long-term benefits for 
their rehabilitation from acquiring positive experience and 
avoiding negative experience through social observation.
In addition to the sustainability of the influence of prior 
experience on placebo/nocebo responses to subsequent treat-
ments, there is less attention to the persistence of placebo/
nocebo responses. Previous studies based on first-person 
experience showed that 1) the persistence of placebo and 
nocebo responses can be influenced by the strength of learn-
ing (ie, the number of conditioning trials),19 and 2) placebo 
analgesia established under continuous reinforcement rather 
than partial reinforcement can be extinguished during the test 
phase,20 whereas nocebo hyperalgesia, once established, seems 
difficult to disappear irrespective of the conditioning sched-
ules (continuous reinforcement and partial reinforcement).21 
In contrast, the persistence of placebo and nocebo responses 
induced by social observation has not been well examined.
In the present study, we aimed at examining the sustained 
effect of prior experience induced by social observation on 
placebo/nocebo responses to subsequent treatments. Based 
on previous studies,3–21 we hypothesized that, as the prior 
experience in person, the experience induced by social obser-
vation would have sustained influence on placebo/nocebo 
responses. In other words, the placebo/nocebo responses 
in an effective prior experience condition would be larger 
than those in an ineffective prior experience condition. 
Furthermore, compared with nocebo hyperalgesia, placebo 
analgesia would be more likely to be extinguished. To test 
these hypotheses, we first investigated the sustainability of 
the effect of either effective or ineffective prior experience, 
acquired a period of time ago through first-person experience 
or social observation, on placebo and nocebo responses to 
subsequent treatments. Second, we included two successive 
tests to explore the difference between nocebo and placebo 
responses generated by the two experience acquisition ways, 
in terms of their persistence.
Materials and methods
Participants
To rule out the possible confounding factors of handedness 
and gender on pain perception and placebo/nocebo effects,17,22 
only right-handed healthy female volunteers were recruited 
in this study (N=82; mean age 20.73±1.56 years). According 
to self-reports, none had history of major medical or psychi-
atric illness, or alcohol or drug abuse. All volunteers were 
informed that the aim of the present study was to investigate 
“the individual difference in pain perception and its psycho-
logical mechanism,” while the true purpose of the study was 
not revealed until the end of the experiment. The study was 
approved by Ethics Committee of Southwest University, and 
informed consent forms were signed by participants before 
the experiment.
Nociceptive stimuli
The electrical nociceptive stimuli were delivered using a 
constant-current stimulator (model DS7A, Digitimer, UK), 
with three stainless-steel concentric bipolar needle electrodes. 
Each electrode consisted of a needle cathode (length: 0.1 
mm, Ø: 0.2 mm) surrounded by a cylindrical anode (Ø: 1.4 
mm), which has been proved to preferentially activate Aδ 
nociceptive fibers in the superficial skin layers.23,24 All three 
electrodes were pasted on the inner side of participants’ left 
forearm according to an equilateral triangle shape. Each 
stimulus consisted of several (ranging from 1 to 20, varied 
within subjects to elicit graded intensity of pain perception) 
rapidly succeeding constant-current, square-wave pulses 
(0.5-ms duration for each pulse), which were presented at 
50 Hz, with an intensity ranging from 0.8 to 3.0 mA (varied 
between subjects to account for the individual difference of 
pain sensitivity).
The method of limits (an ascending series of stimuli 
in steps of 1 mA were delivered starting from subtactile 
threshold until pain sensation was induced25) was applied to 
identify the stimulus intensity and the number of pulses for 
each participant that would elicit a low pain sensation at ~2 
rating, moderate pain sensation at ~5 rating, and high pain 
sensation at ~8 rating on a self-report 11-point Numeric 
Rating Scale (NRS) (0=no sensation, 10=unbearable pain).26 
Participants were familiarized with the electrical stimuli 
before the treatment phase and the conditioning phase. 
Experimental procedure
A random, single-blinded, between-subject experimental 
design was adopted in the present study. As shown in Figure 1, 
the experiment consisted of three phases (ie, treatment phase, 
conditioning phase, and test phase) on two separate days. All 
participants were tested by a female experimenter, who wore 
a white coat and had received systematic training about the 
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Social observation and placebo/nocebo responses
Treatment phase
According to the acquisition way (experience in person vs 
through observation) and effectiveness (effective vs ineffec-
tive) of different prior experience, participants were randomly 
assigned to four experimental groups (Group 1: effective 
first-person experience group; Group 2: effective observation 
experience group; Group 3: ineffective first-person experi-
ence group; Group 4: ineffective observation experience 
group); (Table 1) during the treatment phase (Figure 1).
Participants in each group undertook a total of 36 trials, 
which started with a 1-s white fixation cross centered on the 
monitor with black background in the front of participants at 
a distance of ~50 cm, followed by a visual cue (either a red 
or green dot) lasting for 1 s. For half of the participants, the 
red dot matched with high pain stimuli (ie, high pain cue), 
and the green dot matched with low pain stimuli (ie, low pain 
cue), and vice versa for the other half of the participants, to 
rule out the possible confounding factor of the color of the 
visual cue.16,27 After a 4-s blank, a nociceptive stimulus was 
delivered to participants’ left volar forearm. After another 
4-s blank, participants were required to verbally rate the pain 
intensity on the 11-point NRS. The inter-trial interval (ITI) 
varied randomly between 12 and 16 s. The whole session 
lasted for ~20 min.
More specifically, participants in Group 1 received an 
effective placebo treatment in person, where half of the trials 
presented high pain stimuli (~8 rating on an 11-point self-
report NRS) following the high pain cue, and the remaining 
Figure 1 The experimental design.
Notes: The experimental procedure consisted of three phases on two separate days, including treatment phase, conditioning phase, and test phase (tests 1 and 2). (A) 
Treatment phase. First-person experience refers to receiving treatment in person, and observation experience refers to observing a treatment. For the effective condition, 
visual cues with different colors were paired with nociceptive stimuli with different intensities (low pain cues were paired with low pain stimuli, and high pain cues were paired 
with high pain stimuli). In contrast, for the ineffective condition, low pain cues were paired with low pain stimuli in one half of the trials, but paired with high pain stimuli in 
the other half of the trials (the same for high pain cues). In this phase, participants were randomly assigned to four experimental groups divided by “Acquisition Way” (first-
person/observation experience) and “Effectiveness” (effective/ineffective). “Effective” means the associations between cues and pain stimuli were established. When the low 
pain cues appeared, participants perceived an analgesic effect of the device (the metal ring). When the high pain cues appeared, participants perceived a hyperalgesic effect of 
the device. “Ineffective” means the associations between cues and pain stimuli were not established, and participants could not perceive analgesic effect/hyperalgesic effect. 
Group 1: effective first-person experience group; Group 2: effective observation experience group; Group 3: ineffective first-person experience group; Group 4: ineffective 
observation experience group. (B) Conditioning phase. After 5–6 days, all participants underwent the same conditioning procedure. Visual cues with different colors were 
paired with nociceptive stimuli with different intensities, that is, low pain cues were consistently paired with low pain stimuli, and high pain cues were consistently paired 
with high pain stimuli. (C) Test phase. The test phase was composed of two tests (tests 1 and 2), with a 5-min interval. All visual cues (low pain, control, and high pain) were 
followed by moderate pain stimuli. (D) A representative trial, which was used in all three phases.
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half delivered low pain stimuli (~2 rating on an 11-point 
self-report NRS) following the low pain cue. A metal ring (a 
sham device) served as the placebo and was attached to the 
thumb of participants’ left hands. Participants were informed 
that the intensity of nociceptive stimuli was constant. The low 
pain cues would trigger the device to deliver a sub-threshold 
stimulus that induced an analgesic effect, whereas the high 
pain cues would trigger the device to induce a hyperalgesia 
effect. As a matter of fact, however, the stimulus intensi-
ties associated to the low pain cues were surreptitiously 
decreased, and the stimulus intensities paired with the high 
pain cues were surreptitiously increased. Therefore, after 
receiving the effective placebo treatment, participants would 
perceive an analgesic effect of the device (the metal ring), 
when the low pain cues appear, and a hyperalgesia effect of 
the device, when the high pain cues appear.
In Group 2, participants were asked to watch a self-made 
video where a 24-year-old male demonstrator was receiving 
an effective placebo treatment. The video was recorded in 
the same room, in which the experiment took place. The 
demonstrator was carefully trained to simulate the response 
to an effective placebo treatment prior to the video recording. 
The video showed that the demonstrator was sitting in front 
of a computer screen, with an electrode applied to the left 
volar forearm and a metal ring attached to the left thumb. The 
demonstrator received a sequence of pain stimuli following 
visual cues identical to Group 1 and was required to rate the 
stimulus intensity. Notably, all ratings of pain stimuli were 
predefined, that is, the average ratings to the stimuli follow-
ing low pain cues and high pain cues were 2 and 8 on the 
NRS, respectively. To ensure the participants focused on the 
video, they were required to memorize the number of visual 
cues paired with a rating of >5 and that of <5, respectively.15 
After the observation, participants were told that they would 
undergo an experimental session similar to the demonstrator’s 
experience 5–6 days later.
For Group 3, to ensure that the participants experienced 
an ineffective treatment (ie, the associations between cues 
and pain stimuli cannot be established, that is, participants 
would not perceive an analgesic effect or a hyperalgesic effect 
of the device) in person, the high pain cues were followed 
by 9 high pain stimuli and 9 low pain stimuli, while the low 
pain cues matched with another 9 high pain stimuli and 9 low 
pain stimuli. All stimuli were delivered to participants in a 
pseudorandom sequence. Participants wore the sham device 
and got instructions identical to those in Group 1.
Participants in Group 4 were asked to watch a different 
self-made video, in which the demonstrator received the same 
ineffective placebo treatment as Group 3. Notably, all ratings 
of pain stimuli were also predefined, that is, the average 
ratings to the low pain stimuli and high pain stimuli were 2 
and 8 on NRS, respectively. In contrast, the average ratings 
to the low pain cues and high pain cues were identical. The 
rest procedure was identical to that in Group 2.
Conditioning phase
After 5–6 days, all participants wearing the sham device 
underwent the same experimental procedure during condi-
tioning phase. Specifically, half of the trials presented high 
pain stimuli following high pain cues, and the other half 
delivered low pain stimuli following low pain cues. The rest 
procedure of this phase was the same as Group 1 in treatment 
phase. This whole phase lasted for about 20 min. With this 
phase, we could assess the influence of prior experience, 
either induced by social observation or in person, on the 
newly established placebo and nocebo effects to subsequent 
treatment.
Test phase
To verify the persistence of the analgesia and hyperalgesia 
effects, the test phase was composed of two identical tests (ie, 
test 1 and test 2), with a 5-min interval. In addition to 12 low 
Table 1 Characteristics of participants in each experimental group












F(3, 78) P ηp2
Age (years) 21.23±1.63 20.52±1.50 20.50±1.64 20.63±1.46 1.034 0.382 0.038
PCS 18.55±10.47 16.19±9.92 22.35±12.31 17.89±11.05 1.14 0.336 0.042
STAI-S 38.18±10.82 38.90±7.60 40.35±10.20 39.89±9.24 0.21 0.884 0.008
STAI-T 43.27±8.82 42.29±9.13 43.30±8.82 41.28±9.99 0.08 0.971 0.003
IRI 55.95±9.30 56.57±8.33 55.85±7.56 59.21±7.15 0.724 0.541 0.027
Note: Data are expressed as mean ± SD.
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Social observation and placebo/nocebo responses
pain cues and 12 high pain cues, 12 control cues (ie, white 
dot) were included in each test, and all visual cues were fol-
lowed by moderate pain stimuli with a ~5 rating on the NRS. 
All trials were administered in a pseudorandom sequence. 
Participants were informed that low pain cues anticipated an 
analgesic effect and high pain cues anticipated a hyperalgesia 
effect of the device. In addition, when control cues appeared, 
participants were informed that the device would be turned 
off and there was no modulational effect on the perceived 
pain intensity. The test phase lasted for ~45 min.
Questionnaires
All participants were required to complete three question-
naires before conditioning phase, which included the Chi-
nese versions of the Pain Catastrophizing Scale (PCS),28 the 
State-Trait Anxiety Inventory (STAI),29 and the Interpersonal 
Reactivity Index (IRI).30
The PCS is a 13-item measure of catastrophizing thoughts 
that includes three subscales: Rumination (the inability to 
stop thoughts concerning pain), Magnification (the ten-
dency to exaggerate the threat value of pain stimuli), and 
Helplessness (the feeling of inability to deal with pain). The 
reliability of the Chinese version of the PCS (Cronbach’s 
alpha=0.91, N=153) has been well established.28 The STAI 
(40 items comprising two subscales, ie, STAI-S and STAI-
T) was adopted to assess the anxiety state and anxiety trait, 
with high reliabilities of its subscales (Cronbach’s alpha=0.90 
for STAI-S, Cronbach’s alpha=0.80 for STAI-T, N=2150).29 
Dispositional empathy was measured with the Chinese ver-
sion of the IRI, which consists of 22 items comprising four 
subscales: Perspective Taking (the tendency to adopt other 
people’s point of view), Fantasy Score (the tendency to trans-
pose oneself imaginatively into the feelings and actions of 
fictitious characters in books, movies, and plays), Empathic 
Concern (the tendency to experience feelings of warmth, 
compassion, and concern for others), and Personal Distress 
(the tendency to experience the feelings of personal anxiety, 
discomfort, and unease in reaction to others’ emotions). The 
Chinese version of the IRI has good internal consistency 
(Cronbach’s alpha=0.751, N=529).30 In the current sample, 
reliabilities of the scales were satisfactory: coefficient alphas 
were 0.936 for PCS, 0.913 for STAI-S, 0.890 for STAI-T, 
and 0.745 for IRI.
Statistical analysis
To rule out the possible difference of participants’ character-
istics, we performed one-way analysis of variance (ANOVA) 
on (1) age, (2) catastrophizing, (3) dispositional empathy, (4) 
anxiety state, and (5) anxiety trait among participants in the 
four experimental groups.
To ensure that the manipulation of “Effectiveness” in 
first-person experience groups (Groups 1 and 3) was suc-
cessful, we performed two-way mixed-design ANOVA with 
“Cue” (low pain cues and high pain cues) as within-subject 
factor and “Effectiveness” (effective and ineffective) as 
between-subject factor. Meanwhile, to ensure that the 
manipulation of conditioning procedure in all groups was 
successful, we performed three-way mixed-design ANOVA, 
with “Cue” (low pain cues and high pain cues) as within-
subject factor, “Acquisition Way” (experience in person 
and through observation) and “Effectiveness” as between-
subject factors.
To assess the influence of visual cues, experience acquisi-
tion ways, and effectiveness on pain ratings during the two 
tests, we performed three-way mixed-design ANOVA, with 
“Cue” (low pain cue, control cue, and high pain cue) as 
within-subject factor, “Acquisition Way” and “Effectiveness” 
as between-subject factors. The Huynh–Feldt correction was 
applied in light of observed violations of sphericity assump-
tion,31 and the uncorrected degrees of freedom were reported 
for the convenience of the readers. Post hoc Bonferroni cor-
rections were performed to account for multiple comparisons, 
where necessary. 
We defined the difference between low pain cue– 
associated and control cue–associated ratings as placebo 
effect, and the difference between high pain cue–associated 
and control cue–associated ratings as nocebo effect. To verify 
the persistence of the placebo and nocebo effects, we per-
formed three-way mixed-design ANOVA, with “Test” (test 1 
and test 2) as a within-subject factor, and “Acquisition Way” 
and “Effectiveness” as between-subject factors.
To verify the difference between the placebo effect and 
nocebo effect, we calculated the mean placebo response and 
nocebo response across all four experimental groups for test 1 
and test 2, respectively. The mean values of placebo response 
and nocebo response were compared using paired-samples 
t-tests for each test separately.
All statistical analyses were carried out in SPSS 17.0 
(SPSS Inc., New York, USA), and the statistical significance 
level was set at 0.05. The effect size for ANOVA results in 
the present sample was estimated by partial eta-squared. For 
partial eta-squared, an effect size of 0.0099 is deemed as a 
“small” effect, around 0.0588 as a “medium” effect, and 





























































Powered by TCPDF (www.tcpdf.org)
                               1 / 1







Participants’ characteristics in each experimental group are 
summarized in Table 1. One-way ANOVA showed that there 
was no significant difference among the four experimental 
groups with regard to age and psychological characteristics 
(all P>0.33).
The experimental manipulation during 
treatment and conditioning phases
Two-way mixed-design ANOVA revealed a significant 




=0.957). In addition, the interaction 
between “Effectiveness” and “Cue” was signif icant 
(F(1, 40)=773.991, P<0.001, η
p
2
=0.951). Post hoc tests 
showed that the high pain cue–associated ratings were 
higher than low pain cue–associated ratings (P<0.001) in 
the effective condition. In contrast, there was no significant 
difference between high pain cue–associated ratings and 
low pain cue–associated ratings (P>0.05) in the ineffective 
condition. However, the main effect of “Effectiveness” 
(F(1, 40)=0.781, P=0.382, η
p
2
=0.019) was not significant. 
These results indicated that the manipulation of “Effec-
tiveness” in first-person experience groups was successful 
during the treatment phase, that is, it was “effective” for 
Group 1 but “ineffective” for Group 3.
Meanwhile, three-way mixed-design ANOVA revealed 








=0.083) on pain ratings during the condition-
ing phase. Specifically, the high pain cue–associated ratings 
were higher than low pain cue–associated ratings (P<0.001), 
and the ratings in the effective condition were higher than 
those in the ineffective condition (P=0.010). However, 
the main effect of “Acquisition Way” (F(1, 78)=0.001, 
P=0.978, η
p
2<0.001) was not significant. In addition, 




=0.036), the interaction between 




=0.027), the interaction between “Effectiveness” and 




and the interaction among “Cue”, “Effectiveness”, and 
“Acquisition Way” (F(1, 78)=0.016, P=0.899, η
p
2<0.001) 
were not significant during the conditioning phase. These 
results indicated that the manipulation of conditioning was 
successful in all groups.
Placebo and nocebo responses in tests 1 
and 2
Test 1
Three-way mixed-design ANOVA revealed a significant 




=0.784). Post hoc tests showed that the low 
pain cue–associated ratings were significantly lower than the 
control cue–associated ratings (Group 1: P<0.001; Group 
2: P<0.001; Group 3: P=0.010; Group 4: P=0.008), and the 
high pain cue–associated ratings were significantly higher 
than the control cue–associated ratings (Group 1: P<0.001; 
Group 2: P<0.001; Group 3: P<0.001; Group 4: P=0.001), 
indicating that placebo responses and nocebo responses 
were consistently elicited in all experimental groups during 
test 1 (see Figure 2 upper panel). In addition, the interaction 




=0.412). Post hoc tests showed 
that the low pain cue–associated ratings in the effective 
condition were lower than those in the ineffective condition 
(P<0.001), and the high pain cue–associated ratings in the 
effective condition were higher than those in the ineffective 
condition (P<0.001) (see Figure 3 left panel). 
However, the main effects of “Acquisition Way” 
(F(1, 78)=0.037, P<0.848, η
p
2<0.001) and “Effectiveness” 
(F(1, 78)=1.800, P=0.184, η
p
2
=0.023) were not significant. 
In addition, the interaction between “Cue” and “Acquisi-




interaction between “Effectiveness” and “Acquisition Way” 
(F(1, 78)=0.298, P=0.587, η
p
2
=0.004), and the interaction 
among “Cue,” “Effectiveness,” and “Acquisition Way” 
(F(2, 156)=0.644, P=0.493, η
p
2
=0.008) were not significant.
Test 2
Similar to the results in test 1, three-way mixed-design 
ANOVA revealed a significant main effect of “Cue” on pain 
ratings (F(2, 156)=164.406, P<0.001, η
p
2
=0.678). Post hoc 
tests showed that the low pain cue–associated ratings were 
significantly lower than the control cue–associated ratings 
in Group 1 (P<0.001), Group 2 (P<0.001), and Group 3 
(P=0.027), but not in Group 4 (P=0.224). In contrast, the 
high pain cue–associated ratings were significantly higher 
than the control cue–associated ratings in all experimental 
groups (Group 1: P<0.001; Group 2: P<0.001; Group 3: 
P=0.033; Group 4: P=0.006) (see Figure 2 lower panel). 
The interaction between “Effectiveness” and “Cue” was 
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Social observation and placebo/nocebo responses
Figure 2 The influence of visual cues, experience acquisition ways, and effectiveness on pain ratings.
Notes: The histograms show that mean pain ratings to the nociceptive stimuli followed the low pain cues, the control cues, and the high pain cues, in each experimental 
group during test 1 (upper panel) and test 2 (lower panel). The low pain cue–associated ratings were significantly lower than the control cue–associated ratings, and the 
high pain cue–associated ratings were significantly higher than the control cue–associated ratings for each group both in tests 1 and 2, except for Group 4 in test 2. *P<0.05; 
**P<0.01; ***P<0.001.
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Figure 3 The significant interaction between “Effectiveness” and “Cue” on pain ratings.
Notes: Significant interactions between “Effectiveness” and “Cue” were observed in both tests 1 and 2. **P<0.01; ***P<0.001.
Abbreviations: NRS, Numeric Rating Scale; ns, not significant.
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in the effective condition were lower than those in the 
ineffective condition (P=0.002), and the high pain cue– 
associated ratings in the effective condition were higher 
than those in the ineffective condition (P<0.001) (see 
Figure 3 right panel).
However, the main effects of “Acquisition Way” (F(1, 
78)=0.362, P<0.549, η
p




=0.004) were not significant. The 
interaction between “Cue” and “Acquisition Way” (F(2, 
156)=0.007, P=0.985, η
p
2<0.001), the interaction between 




=0.004), and the interaction among “Cue,” 




=0.001) were not significant. 
The influence of prior experience on 
placebo and nocebo responses
Placebo response
Three-way mixed-design ANOVA revealed significant 








on the placebo response, that is, the difference between low 
pain cue–associated and control cue–associated ratings. 
In contrast, the main effect of “Acquisition Way” (F(1, 
78)=0.027, P=0.871, η
p
2<0.001), the interaction between 




=0.002), the interaction between “Acquisition 








=0.007), and the interaction among 




=0.030) were not significant. These 
results indicated that the placebo response in the effective 
condition was significantly larger than that in the ineffective 
condition regardless of the way to acquire the prior experi-
ence, and the placebo response in test 2 was significantly 
smaller than that in test 1 (see Figure 4 left panel), indicating 
that the placebo response was easy to be extinguished.
Nocebo response
Three-way mixed-design ANOVA revealed a signif i-




=0.419) on the nocebo response, that is, the 
difference between high pain cue–associated and control 
cue– associated ratings. In contrast, the main effects of 
“Acquisition Way” (F(1, 78)=0.005, P=0.944, η
p
2<0.001) 
and “Test” (F(1, 78)=2.909, P=0.092, η
p
2
=0.036), as well as 
the interaction between “Acquisition Way” and “Effective-
ness” (F(1, 78)=0.187, P=0.666, η
p
2
=0.002), the interaction 




=0.002), the interaction between “Effective-




the interaction among “Acquisition Way,” “Effectiveness,” 
and “Test” (F(1, 78)=2.050, P=0.156, η
p
2
=0.026) were not 
significant. These results indicated that the nocebo response 
in the effective condition was significantly more profound 
than that in the ineffective condition regardless of the way 
to acquire the prior experience. Different from the placebo 
effect, no significant difference of the nocebo response was 
observed between tests 1 and 2 (see Figure 4 right panel). 
The comparison between placebo and 
nocebo responses
As can be seen in Figure 5, the nocebo response was sig-
nificantly larger than the placebo response in both test 1 
(t (81)=−3.23; P=0.002, two-tailed) and test 2 (t (81) =−3.44; 
Figure 4 The influence of prior experience on placebo and nocebo responses.
Notes: The placebo response (the difference between low pain cue–associated and control cue–associated ratings; left panel) and the nocebo response (the difference 
between high pain cue–associated and control cue–associated ratings; right panel) were displayed for each experimental group in tests 1 and 2. **P<0.01; ***P<0.001.
Abbreviation: ns, not significant.
0
Test 1
Group 1 Group 2 Group 3 Group 4























































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Social observation and placebo/nocebo responses
P=0.001, two-tailed), indicating that our experimental design 
had a greater effect on the expectancy of aversive events.
Discussion
There were two salient observations from the present results. 
First, experience gained 5–6 days ago in person and through 
social observation both can affect placebo and nocebo effects 
to subsequent treatments, and the response magnitudes of the 
two experience acquisition ways were comparable. In other 
words, both placebo and nocebo responses in the effective 
condition were significantly larger than those in the ineffec-
tive condition, regardless of the acquisition ways of prior 
experience. Second, once placebo and nocebo effects were 
elicited, nocebo effect was likely to persist, while placebo 
effect was easy to diminish. 
The sustainability of placebo and nocebo 
effects to subsequent treatments
Both first-person and social observation prior experience 
obtained a while ago (5–6 days in our case) can affect pla-
cebo and nocebo responses to subsequent treatments, with 
no difference in the magnitudes of the placebo and nocebo 
responses between two acquisition ways.
One possible explanation is that experience obtained 
through social observation has comparable potentials as 
first-person experience in affecting perceived effectiveness of 
treatments. Similar to the first-person experience, experience 
obtained by social observation can increase or decrease expec-
tancies on analgesia and hyperalgesia effects,12 depending on 
what has been observed. Given its extremely essential role in 
survival, analgesia and hyperalgesia information tends to be 
consolidated into long-term memory.33 Therefore, when the 
observer undergoes a similar circumstance even after several 
days, analgesia and hyperalgesia information can be recalled 
easily to facilitate the processes of potentially rewarding 
events and harmful events, respectively. This finding pro-
vides further evidence to support Bandura’s social cognitive 
learning theory,3 which emphasizes that the learning process 
initiated by social observation not only includes recognition 
of observed information, but also involves encoding and 
storage of this information in an easily remembered form to 
shape observer’s experience.3,34 Indeed, when the observer 
undergoes a similar condition after observing a demonstra-
tor receiving analgesic and hyperalgesic treatments, the 
retentive information can be easily extracted to rehearse 
the demonstrator’s responses (eg, placebo analgesia/nocebo 
hyperalgesia).15 The neural mechanisms of placebo analgesia 
and nocebo hyperalgesia induced by prior experience through 
social observation might rely on the existence of the mirror 
neuron system responsible for the processing and storage of 
outcomes learned by observing others.35 Alternatively, it is 
also possible that first-person and social observational experi-
ence obtained 5–6 days ago affect perceived effectiveness of 
treatments differently. The absence of a difference as a func-
tion of “Acquisition Way” might be due to the conditioning 
phase prior to the test phase, which may interact with the prior 
experience, regardless of how it was gained, thereby resulting 
in comparable placebo and nocebo responses.
In addition, prior experience obtained via effective con-
ditioning procedure induced significantly larger placebo and 
nocebo responses to subsequent treatments in comparison 
to those obtained via ineffective conditioning procedure, 
regardless of the acquisition ways (ie, experience in person 
or through observation). This finding is in line with previous 
studies focusing on how effectiveness of prior experience in 
person affects placebo responses,12,36 and consistent with the 
study of Kessner et al,13,37 which indicated that treatment-
related experience critically determines the response to the 
second, different analgesic treatment.
There might be two distinct mechanisms underlying the 
effectiveness effect. One may rely on the modification on 
response expectancy. As suggested by response expectancy 
theory, personal responses could be altered by changing indi-
viduals’ expectancy.8,38–41 It has been suggested that positive 
expectancy plays an important role in triggering the release 
of endogenous opioids and then produces placebo analgesia,42 
Figure 5 The comparison of placebo and nocebo responses.
Notes: The nocebo response was significantly larger than the placebo response 
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whereas expecting a negative outcome (hyperalgesia) may 
trigger the release of cholecystokinin, which in turn produces 
nocebo hyperalgesia.8,43 Specifically, high expectancy level 
could enhance placebo and nocebo responses to the treatment 
of pain, while relative low expectancy level could weaken 
such responses.44–46 In line with the response expectancy 
theory, effective prior experience, gained in person or through 
observation, might be associated with increased expectancy, 
leading to substantial placebo and nocebo responses. In 
contrast, ineffective prior experience could not enhance 
the level of expectancy, therefore generating comparatively 
weak placebo and nocebo responses. Consistent with this 
theory, a previous neuroimaging study showed that a strong 
placebo induced better analgesic efficacy than a weak pla-
cebo, and the response in rostral anterior cingulate cortex 
was significantly higher to the strong placebo than to the 
weak placebo.47 It indicated that the efficacy of placebo treat-
ments depended on participants’ expectancy, which was, at 
least partly, shaped by previous experiences. The efficacy of 
placebo treatments may rely on the learning process, as the 
influence of treatment history could transfer over time and 
over therapeutic approaches.37 Zunhammer et al found that 
the negative carry-over effects on treatment efficacy were 
not counteracted by the expectations of positive treatment 
effects (induced by changing the drug administration way) in 
the subjects, which indicated that learned carry-over effects 
generalize over time and across routes of drug administration 
regardless of conscious expectations.48
The persistence of placebo and nocebo 
effects
We observed a reduced placebo response in test 2 compared 
with that in test 1, whereas nocebo response measured within 
the two tests were not discriminable, indicating that nocebo 
effect is more likely to persist at least in the two tests. Dif-
ferences in the persistence of placebo and nocebo effects 
might be associated with the strength of learning.19 On the 
other hand, given that the test phase can be considered as 
an extinction process (extinction process is also one kind of 
learning process),12 the observed differences in terms of the 
persistence of the placebo and nocebo effects might result 
from their differences in extinction processes. This finding 
is consistent with previous studies suggesting that nocebo 
hyperalgesia is difficult to be extinguished once established 
via conditioning procedure.20,21 Furthermore, the nocebo 
response was more pronounced than the placebo response 
across all four experimental groups in the two tests, and a 
similar finding has been reported in a previous study.49 From 
an evolutionary standpoint, threat-related signals are more 
salient than safety-related signals for detecting potential 
changes of the environment.50–53 Nocebo responses, therefore, 
represent a valuable adaptation to enhance the perceptual 
processing and anticipation of negative outcomes in response 
to the challenges in the environment, which facilitates the 
initiation of potentially defensive behaviors.54 That is, once 
the acquisition of nocebo effect succeeded, its natural extinc-
tion processes slowly, eventually resulting in the maintenance 
of the information over time. 
Study limitations
Several research questions related to this study need to 
be addressed in further investigations. For instance, only 
right-handed female participants were enrolled, and this 
may restrict the generalization of the experimental results. 
Moreover, expectancy and state anxiety were not assessed, 
therefore limiting our understanding about the weight of 
participants’ expectancy and state anxiety on placebo/nocebo 
effects. In addition, it may require an additional group with no 
prior experience as a “baseline” to reveal either prior exposure 
to an effective treatment enhanced the following conditioning 
effect, or prior exposure to an ineffective treatment muted it.
Clinical implications
Our observations have two important clinical implications. 
First, our study highlights that the influences of prior expe-
rience gained through social observation on the placebo/
nocebo response are similar to those of prior experience 
obtained in person, and that the effective condition induced 
more pronounced placebo/nocebo responses than the ineffec-
tive condition. Therefore, it is important for clinical practice 
to increase positive prior experience generating placebo 
analgesia and to decrease negative prior experience produc-
ing nocebo hyperalgesia,55 through not only first-person 
experience, but also social observation. Enhanced placebo 
effect and/or reduced nocebo effect would promote patients’ 
rehabilitation by optimizing their treatment expectancy. 
Second, it is worth noting that the nocebo response was 
more significant than the placebo response, and nocebo 
response is more likely to persist. Thus, the negative prior 
experience generating nocebo hyperalgesia should be 
emphasized in clinical applications, as it is likely to trigger 
a undesirable response to subsequent treatments, which 
would increase the severity of symptoms immediately and 
persistently. For instance, doctors may need to mind their 
behaviors and attitudes toward patients, given that negative 
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Social observation and placebo/nocebo responses
patients’ health.56 Attention to the extinction of the existed 
experience with negative responses (eg, nocebo hyperalgesia) 
should be warranted in the future.
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